With a new year comes new expectations. 24/7 Wall St. has generated a bullish and bearish scenario for 2014 in each stock of the Dow, including Pfizer and rival Merck & Co.
If one firm can create interest around a stock, it is Goldman Sachs. Investors have followed its Conviction Buy List for years, but 24/7 Wall St. has tracked many major changes to…
ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has acquired rights to launch its…
thinkstockDecember 11, 2013: Markets opened lower again on Wednesday morning on another day of relatively light trading and yet more profit-taking. The DJIA closed down 0.81%, the S&P 500 closed down 1.13%,…
courtesy of VerizonThe short interest data for the end of November is out, and the results are somewhat surprising when it comes to the top high-yield safe dividends out there. Some of the…
GS.COMIt is that time of year when investors start positioning their portfolios for the year ahead. 24/7 Wall St. reviews vast numbers of research reports looking for the best stocks to buy…
ThinkstockThere is a trend at the end of each year followed by many income investors. This is the Dogs of the Dow, which is simply made up of the 10 Dow Jones…
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Tuesday, December 3, 2013. They include Apple, 3D Systems, Micron Technology and Tesla Motors.
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that the total…
We have now seen the short interest reports from the October 31 settlement date and have compared them to the October 15 settlement date. This is important because it reflects the opinions…
Wikimedia CommonsPfizer Inc. (NYSE: PFE) reported third-quarter 2013 results before markets opened Tuesday morning. The drug maker posted adjusted diluted earnings per share (EPS) of $0.58 and revenues of $12.64 billion. In…
Paul Ausick The drug patent cliff for Big Pharma is coming with some continued consequences, and two drug giants with earnings this week are Dow Jones Industrial Average components. Merck & Co. (NYSE: MRK) reported…
courtesy of Verizon WirelessMergers and acquisitions (M&A) sometimes can be an excellent measure of the economy’s financial health. However, since there is a great deal of evidence that most M&A results are…
Jon OggEarnings season is in full swing and this coming week will bring many key earnings reports. This will also be the last week of major on-calendar earnings for the third quarter,…
We have seen the short interest reports for the October 15 settlement date. It turns out that short sellers have been getting out of the way of the bull market after previously…
